Evidence at scale, breakthroughs at speed
Flatiron Health at ASCO 2025
Booth #11131
Get a preview of Panoramic Data from Dr. Emily Castellanos, Head of Research Oncology, Clinical Solutions at Flatiron
From R&D to post-market studies, Flatiron is your trusted partner in delivering oncology evidence.
Connect with us at ASCO to:
-
Leverage retrospective and prospective evidence tailored to your research objectives and regulatory needs.
-
See how teams across precision medicine, R&D, RWE, HEOR, clinical development, medical affairs, and commercial functions use Flatiron’s end-to-end solutions to generate actionable insights.
-
Explore our industry-leading real-world data offerings—including linked clinical-multiomics data, Panoramic Data, and multinational datasets from the UK, Germany, and Japan—for deeper insights and broader patient analyses.
-
Learn how our clinical research services—from tech-enabled patient identification and data capture to end-to-end study design and execution—help life sciences partners accelerate and streamline their research.
Flatiron experts at ASCO
Stop by booth #11131 to meet one of our scientific and medical experts, learn more about our vast, contemporaneous real-world data, and discover what it looks like to work with our engaged research community.
Our research
Flatiron is excited to share our accepted research at this year’s conference. Check back on May 23 for a more in-depth look at research, both poster presentations and online acceptances, for this year.
POSTER PRESENTATIONS
Racial and ethnic differences in biomarker testing for targetable alterations among patients with HR+ HER2- metastatic breast cancer (mBC)
See this research
Date: Monday, June 2
Time: 9 AM - 12 PM CDT
Breast Cancer—Metastatic
Poster Board: 63
Abstract number: 1084
Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)
See this research
Date: Monday, June 2
Time: 9 AM - 12 PM CDT
Breast Cancer — Local/Regional/Adjuvant
Poster Board: 148
Abstract number: 555
Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): insights by PTEN status
See this research
Date: Monday, June 2
Time: 9 AM - 12 PM CDT
Genitourinary—Prostate, Testicular, and Penile
Poster Board: 295
Abstract number: 5096
Impact of social determinants of health on mortality in diffuse large b-cell lymphoma (DLBCL) using real-world data
See this research
Date: Saturday, May 31
Time: 1:30 - 4:30 PM CDT
Quality Care/Health Services Research
Poster Board: 436
Abstract number: 11097
Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in US patients with stage II/III non-small cell lung cancer
See this research
Date: Saturday, May 31
Time: 1:30 - 4:30 PM CDT
Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Board: 199
Abstract number: 8078
Molecular residual disease (MRD) in solid tumors
See this research
Date: Monday, June 2
Time: 1:30 - 4:30 PM CDT
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Poster Board: 486b
Abstract number: TPS3186
Featured solutions
Real-World Data
Our flexible real-world data configurations are tailored to address the specific needs of your oncology portfolio and now encompass more than 5 million patient journeys, 4 of the largest oncology markets in the world, 22+ tumor types, and multimodal data.
Real-World Evidence Services
Flatiron’s in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your oncology portfolio, from refining target product profiles, to conducting comparative effectiveness studies and supporting regulatory and HTA submissions.
Flatiron Trials
We help sponsors generate prospective evidence through the pragmatic design and execution of interventional trials and prospective observational studies enabled by our oncology-specific CRO services, tech-enabled site network, and purpose-built research technology.
Patient Identification by Flatiron
We accelerate trial enrollment by deploying high-quality, contemporaneous RWD, expert human review, and patient matching technology to recommend the optimal academic and community sites to open your trials and surface eligible patients for your trials directly to the care team in the EHR.
Featured content
From portfolio strategy to post-market trials, there are many opportunities to utilize evidence as long as you have the right partner. Discover what we will be showcasing at ASCO this year with a selection of some of our highest impact work.
How advances in molecular profiling and linked real-world clinico-omics data are launching a new era of precision oncology
Recent advances in molecular profiling have revolutionized precision oncology, leading to more personalized and effective cancer treatments. However, barriers such as incomplete biomarker testing and disparities in access remain, highlighting the need for high-quality, representative real-world clinico-multiomic datasets. The Flatiron-Caris Clinical-Molecular Database (CMDB) addresses these gaps by linking robust clinical and molecular data, empowering researchers to uncover new therapeutic targets and improve patient outcomes in real-world settings.
Connect with a Flatiron Expert
Kristi Savill, PhD
Director, Scientific Engagement for Precision Oncology
From entry to insights: How AI is transforming the clinical data journey
Flatiron Health is leveraging AI, specifically LLMs, to extract clinically meaningful information from electronic health records (EHRs), making patient data more accessible and actionable for research and treatment. This article highlights the rigorous processes behind ensuring AI-generated data is accurate, complete, and reliable, including expert validation, iterative refinement, and bias assessment. By combining AI with human expertise, Flatiron aims to enhance real-world data insights, ultimately improving outcomes for people with cancer.
Connect with a Flatiron Expert
Aaron Cohen, MD, MSCE
Head of Research Oncology, Clinical Data
Oncology trials: A new approach to Improve accuracy and alleviate burden associated with patient identification
At the 2024 ASCO Quality Care Symposium, Flatiron Health presented a new service to help sites screen patients based on a novel combination of structured EHR data, machine learning, and human abstraction. In this Q&A, hear Dr. Anosheh Afghaghi unpacks how Flatiron’s unique approach can lead to substantial improvements in the patient screening and recruitment process.
Connect with a Flatiron Expert
Anosheh Afghahi, MD, MPH
Medical Director, Research Oncology
A pragmatic approach to prospective evidence generation in clinical trials
Despite recent advancements, clinical researchers face persistent problems that impede the path to innovation. In this video podcast, Flatiron’s Head of Prospective Studies, Client Solutions Josh Buddle discusses his start in clinical research, how the industry has evolved throughout his career, and how we can move towards more efficient and inclusive trials with reduced burden for sites and patients.
Connect with a Flatiron Expert
Josh Buddle
Head of Prospective Studies, Client Solutions
Pragmatism in Practice: Implementing pragmatic elements in modern oncology clinical studies
What does the phrase “pragmatic clinical studies” mean to you? At Flatiron, we’ve heard various definitions, but most agree that it’s ultimately about designing studies with elements that are more reflective of routine clinical practice. In this playbook, we unpack study design elements that are ripe for pragmatism, four steps you can take to apply pragmatic elements, and the types of studies where pragmatic design can have the biggest impact.
Connect with a Flatiron Expert
Majd Ghanim, MD MSCR
Medical Director, Research Oncology
Want to learn more about how Flatiron’s Evidence Solutions can support research across your portfolio?
Leverage Flatiron’s industry-leading oncology solutions to unlock global insights in cancer research, including:
- Panoramic data with maximum cohort sizes spanning disease settings from our network of over 5M patients with cancer
- >78K patients linked across Flatiron’s best-in-class longitudinal clinical data and Caris’ industry leading molecular data
- Local real-world data (RWD) cohorts in the U.S., UK, Germany and Japan
- Full trial execution powered by integrated clinical research technology and end-to-end CRO services
- Tech-enabled patient identification and data capture to streamline clinical research